{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:39Z","timestamp":1792788459833,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Ferrara","id":[{"id":"https:\/\/ror.org\/041zkgm14","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"DOI":"10.1007\/s11357-025-02052-3","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:35:05Z","timestamp":1765805705000},"page":"7191-7202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia"],"prefix":"10.1007","volume":"48","author":[{"given":"Giovanni","family":"Zuliani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3907-0770","authenticated-orcid":false,"given":"Gloria","family":"Brombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Polastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5103-4496","authenticated-orcid":false,"given":"Francesco di Paola","family":"Dario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zuin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"1","key":"2052_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/gps.1402","volume":"21","author":"A Takeda","year":"2006","unstructured":"Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2006;21(1):17\u201328. https:\/\/doi.org\/10.1002\/gps.1402.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2052_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108352","volume":"190","author":"G Marucci","year":"2021","unstructured":"Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Neuropharmacology. 2021;190:108352. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108352.","journal-title":"Neuropharmacology"},{"issue":"1","key":"2052_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005593","volume":"2006","author":"J Birks","year":"2006","unstructured":"Birks J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;2006(1):CD005593. https:\/\/doi.org\/10.1002\/14651858.CD005593.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2052_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-023-02675-6","volume":"36","author":"G Zuliani","year":"2024","unstructured":"Zuliani G, Zuin M, Romagnoli T, Polastri M, Cervellati C, Brombo G. Acetyl-cholinesterase-inhibitors reconsidered. A narrative review of post-marketing studies on Alzheimer\u2019s disease. Aging Clin Exp Res. 2024;36(1):23. https:\/\/doi.org\/10.1007\/s40520-023-02675-6.","journal-title":"Aging Clin Exp Res"},{"issue":"20","key":"2052_CR5","doi-asserted-by":"publisher","first-page":"e2313","DOI":"10.1212\/WNL.0000000000201161","volume":"99","author":"C Truong","year":"2022","unstructured":"Truong C, Recto C, Lafont C, Canoui-Poitrine F, Belmin JB, Lafuente-Lafuente C. Effect of cholinesterase inhibitors on mortality in patients with dementia: a systematic review of randomized and nonrandomized trials. Neurology. 2022;99(20):e2313\u201325. https:\/\/doi.org\/10.1212\/WNL.0000000000201161.","journal-title":"Neurology"},{"key":"2052_CR6","unstructured":"National Institute for Health and Care Excellence (UK). Dementia: Assessment, management and support for people living with dementia and their carers. London: National Institute for Health and Care Excellence (NICE); 2018.\u00a0https:\/\/www.nice.org.uk\/guidance\/ng97"},{"issue":"9","key":"2052_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/gps.1759","volume":"22","author":"M Bhasin","year":"2007","unstructured":"Bhasin M, Rowan E, Edwards K, McKeith I. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int J Geriatr Psychiatry. 2007;22(9):890\u20135. https:\/\/doi.org\/10.1002\/gps.1759.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"9314","key":"2052_CR8","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","volume":"359","author":"T Erkinjuntti","year":"2002","unstructured":"Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359(9314):1283\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(02)08267-3.","journal-title":"Lancet"},{"issue":"3","key":"2052_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"2052_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009081.pub2","volume":"2","author":"C Parsons","year":"2021","unstructured":"Parsons C, Lim WY, Loy C, et al. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database Syst Rev. 2021;2(2):CD009081. https:\/\/doi.org\/10.1002\/14651858.CD009081.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9516","key":"2052_CR11","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","volume":"367","author":"B Winblad","year":"2006","unstructured":"Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer\u2019s disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367(9516):1057\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(06)68350-5.","journal-title":"Lancet"},{"issue":"5","key":"2052_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1212\/01.wnl.0000266627.96040.5a","volume":"69","author":"SE Black","year":"2007","unstructured":"Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69(5):459\u201369. https:\/\/doi.org\/10.1212\/01.wnl.0000266627.96040.5a.","journal-title":"Neurology"},{"issue":"5","key":"2052_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000122961","volume":"25","author":"A Homma","year":"2008","unstructured":"Homma A, Imai Y, Tago H, et al. Donepezil treatment of patients with severe Alzheimer\u2019s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord. 2008;25(5):399\u2013407. https:\/\/doi.org\/10.1159\/000122961.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"2052_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1474-4422(08)70261-8","volume":"8","author":"A Burns","year":"2009","unstructured":"Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer\u2019s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2009;8(1):39\u201347. https:\/\/doi.org\/10.1016\/S1474-4422(08)70261-8.","journal-title":"Lancet Neurol"},{"key":"2052_CR15","unstructured":"Kuns B, Rosani A, Patel P, Varghese D. Memantine. [Updated 2024 Jan 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500025\/"},{"issue":"14","key":"2052_CR16","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, St\u00f6ffler A, et al. Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med. 2003;348(14):1333\u201341. https:\/\/doi.org\/10.1056\/NEJMoa013128.","journal-title":"N Engl J Med"},{"key":"2052_CR17","doi-asserted-by":"publisher","unstructured":"McShane R, Westby MJ, Roberts E, et al. Memantine for dementia.\u00a0Cochrane Database Syst Rev. 2019;3(3):CD003154. https:\/\/doi.org\/10.1002\/14651858.CD003154.pub6R","DOI":"10.1002\/14651858.CD003154.pub6R"},{"issue":"7","key":"2052_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005158","volume":"4","author":"K Stubendorff","year":"2014","unstructured":"Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson\u2019s disease with dementia: a prospective study. BMJ Open. 2014;4(7):e005158. https:\/\/doi.org\/10.1136\/bmjopen-2014-005158.","journal-title":"BMJ Open"},{"issue":"7","key":"2052_CR19","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1161\/01.str.0000020094.08790.49","volume":"33","author":"JM Orgogozo","year":"2002","unstructured":"Orgogozo JM, Rigaud AS, St\u00f6ffler A, M\u00f6bius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834\u20139. https:\/\/doi.org\/10.1161\/01.str.0000020094.08790.49.","journal-title":"Stroke"},{"issue":"3","key":"2052_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317\u201324. https:\/\/doi.org\/10.1001\/jama.291.3.317.","journal-title":"JAMA"},{"issue":"10","key":"2052_CR21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"R Howard","year":"2012","unstructured":"Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N Engl J Med. 2012;366(10):893\u2013903. https:\/\/doi.org\/10.1056\/NEJMoa1106668.","journal-title":"N Engl J Med"},{"issue":"2","key":"2052_CR22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3233\/JAD-132735","volume":"41","author":"P Gareri","year":"2014","unstructured":"Gareri P, Putignano D, Castagna A, et al. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer\u2019s Disease: the MEMAGE study. J Alzheimers Dis. 2014;41(2):633\u201340. https:\/\/doi.org\/10.3233\/JAD-132735.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2052_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3233\/JAD-130662","volume":"36","author":"LC Lazzeroni","year":"2013","unstructured":"Lazzeroni LC, Halbauer JD, Ashford JW, et al. Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008. J Alzheimers Dis. 2013;36(4):791\u20138. https:\/\/doi.org\/10.3233\/JAD-130662.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"2052_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/wnl.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34(7):939\u201344. https:\/\/doi.org\/10.1212\/wnl.34.7.939.","journal-title":"Neurology"},{"issue":"3 Suppl","key":"2052_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3233\/jad-2006-9s347","volume":"9","author":"IG McKeith","year":"2006","unstructured":"McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9(3 Suppl):417\u201323. https:\/\/doi.org\/10.3233\/jad-2006-9s347.","journal-title":"J Alzheimers Dis"},{"key":"2052_CR26","doi-asserted-by":"publisher","unstructured":"Rom\u00e1n GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.\u00a0Neurology. 1993;43(2):250\u2013260. https:\/\/doi.org\/10.1212\/wnl.43.2.250","DOI":"10.1212\/wnl.43.2.250"},{"key":"2052_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-9-29","volume":"9","author":"P Pezzotti","year":"2008","unstructured":"Pezzotti P, Scalmana S, Mastromattei A, Di Lallo D. The accuracy of the MMSE in detecting cognitive impairment when administered by general practitioners: a prospective observational study. BMC Fam Pract. 2008;9:29. https:\/\/doi.org\/10.1186\/1471-2296-9-29.","journal-title":"BMC Fam Pract"},{"issue":"1","key":"2052_CR28","doi-asserted-by":"publisher","first-page":"12214","DOI":"10.1038\/s41598-022-16476-w","volume":"12","author":"M Zuin","year":"2022","unstructured":"Zuin M, Cherubini A, Volpato S, Ferrucci L, Zuliani G. Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia. Sci Rep. 2022;12(1):12214. https:\/\/doi.org\/10.1038\/s41598-022-16476-w.","journal-title":"Sci Rep"},{"issue":"2","key":"2052_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/WAD.0b013e318065c495","volume":"21","author":"CH van Dyck","year":"2007","unstructured":"van Dyck CH, Tariot PN, Meyers B. Malca Resnick E; memantine MEM-MD-01 Study Group. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):136\u201343. https:\/\/doi.org\/10.1097\/WAD.0b013e318065c495.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"2052_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70071","volume":"11","author":"V Zolnowski-Kolp","year":"2025","unstructured":"Zolnowski-Kolp V, Oquendo B, Havreng-Th\u00e9ry C, Lafuente-Lafuente C, Belmin J. Effect of long-term treatment with memantine on mortality in patients with major cognitive disorders: a systematic review and meta-analysis. Alzheimers Dement (N Y). 2025;11(2):e70071. https:\/\/doi.org\/10.1002\/trc2.70071.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"10","key":"2052_CR31","doi-asserted-by":"publisher","first-page":"6740","DOI":"10.1002\/alz.14118","volume":"20","author":"H Xu","year":"2024","unstructured":"Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M. Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: an up to 10-year follow-up study. Alzheimers Dement. 2024;20(10):6740\u201354. https:\/\/doi.org\/10.1002\/alz.14118.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2052_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-000917","volume":"2","author":"LE Farrimond","year":"2012","unstructured":"Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer\u2019s disease: a systematic review. BMJ Open. 2012;2(3):e000917. https:\/\/doi.org\/10.1136\/bmjopen-2012-000917.","journal-title":"BMJ Open"},{"issue":"1","key":"2052_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01481-0","volume":"16","author":"C Havreng-Th\u00e9ry","year":"2024","unstructured":"Havreng-Th\u00e9ry C, Oquendo B, Zolnowski-Kolp V, et al. Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study. Alzheimers Res Ther. 2024;16(1):117. https:\/\/doi.org\/10.1186\/s13195-024-01481-0.","journal-title":"Alzheimers Res Ther"},{"key":"2052_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109737","volume":"244","author":"P Karimi Tari","year":"2024","unstructured":"Karimi Tari P, Parsons CG, Collingridge GL, Rammes G. Memantine: updating a rare success story in pro-cognitive therapeutics. Neuropharmacology. 2024;244:109737. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109737.","journal-title":"Neuropharmacology"},{"key":"2052_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173277","volume":"882","author":"K Jannesar","year":"2020","unstructured":"Jannesar K, Abbaszadeh S, Malekinejad H, Soraya H. Cardioprotective effects of memantine in myocardial ischemia: ex vivo and in vivo studies. Eur J Pharmacol. 2020;882:173277. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173277.","journal-title":"Eur J Pharmacol"},{"issue":"17","key":"2052_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14176003","volume":"14","author":"N Waszkiewicz","year":"2025","unstructured":"Waszkiewicz N. The future of oncology in psychiatric medications. J Clin Med. 2025;14(17):6003. https:\/\/doi.org\/10.3390\/jcm14176003.","journal-title":"J Clin Med"},{"issue":"5","key":"2052_CR37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.amjopharm.2011.08.004","volume":"9","author":"D Mansour","year":"2011","unstructured":"Mansour D, Wong R, Kuskowski M, Dysken M. Discontinuation of acetylcholinesterase inhibitor treatment in the nursing home. Am J Geriatr Pharmacother. 2011;9(5):345\u201350. https:\/\/doi.org\/10.1016\/j.amjopharm.2011.08.004.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"9","key":"2052_CR38","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1111\/jgs.15985","volume":"67","author":"JD Niznik","year":"2019","unstructured":"Niznik JD, Zhao X, He M, et al. Factors associated with deprescribing acetylcholinesterase inhibitors in older nursing home residents with severe dementia. J Am Geriatr Soc. 2019;67(9):1871\u20139. https:\/\/doi.org\/10.1111\/jgs.15985.","journal-title":"J Am Geriatr Soc"},{"issue":"11-12","key":"2052_CR39","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/(sici)1097-0258(20000615\/30)19:11\/12<1607::aid-sim449>3.0.co;2-o","volume":"19","author":"MS Mendiondo","year":"2000","unstructured":"Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA. Modelling mini mental state examination changes in Alzheimer\u2019s disease. Stat Med. 2000;19(11\u201312):1607\u201316. https:\/\/doi.org\/10.1002\/(sici)1097-0258(20000615\/30)19:11\/12<1607::aid-sim449>3.0.co;2-o.","journal-title":"Stat Med"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-02052-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-02052-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-02052-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:20:32Z","timestamp":1790140832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-02052-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2052"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-02052-3","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"For our study we used data collected in the large multicenter NACC Uniform Data Set (UDS), a dataset that included participant information collected from approximately 34 current or former Alzheimer\u2019s Disease Research Centers (ADRCs) funded by the National Institute on Aging. All contributing ADRCs were required to obtain written informed consent from their participants and maintain their own separate evaluation and approval from their institutional review board before submitting data to the NACC. The present study was reviewed and approved by NACC Research Review Group.","order":1,"name":"Ethics","label":"Ethics and consent to participate declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}